The Making of Leukemia

International Journal of Molecular Sciences
Inés Gonzalez-HerreroCarolina Vicente-Dueñas

Abstract

Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of leukemia. Studies on different types of hematopoietic tumors have shown that the contribution of oncogenes to leukemia is mainly mediated through the epigenetic reprogramming of the leukemia-initiating target cell. This driving of cancer by a malignant epigenetic stem cell rewiring is, however, not exclusive of the hematopoietic system, but rather represents a common tumoral mechanism that is also at work in epithelial tumors. Tumoral epigenetic reprogramming is therefore a new type of interaction between genes and their target cells, in which the action of the oncogene modifies the epigenome to prime leukemia development by establishing a new pathological tumoral cellular identity. This reprogramming may remain latent until it is triggered by either endogenous or environmental stimuli. This new view on the making of leukemia not only reveals a novel function for oncogenes, but also provides evidence for a pre...Continue Reading

References

Oct 1, 1977·The Journal of Clinical Investigation·A Hamburger, S E Salmon
Aug 10, 1999·Nature·L ChinR A DePinho
Dec 30, 1999·Nature Genetics·C S HuettnerD G Tenen
Jul 6, 2002·Science·I Bernard Weinstein
Apr 3, 2003·Nature Reviews. Cancer·Ruth EtzioniLeland Hartwell
Feb 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy R RebbeckBarbara L Weber
Aug 4, 2004·Genes & Development·Konrad HochedlingerRudolf Jaenisch
Jan 5, 2005·Nature Reviews. Cancer·Bruce A Chabner, Thomas G Roberts
Nov 28, 2008·The EMBO Journal·María Pérez-CaroIsidro Sánchez-García
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 29, 2009·Nature·Valery Krizhanovsky, Scott W Lowe
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jun 13, 2012·Proceedings of the National Academy of Sciences of the United States of America·Carolina Vicente-DueñasJose A Martinez-Climent
Jul 25, 2012·Cell Cycle·Carolina Vicente-DueñasIsidro Sánchez-García
Aug 31, 2012·Science Translational Medicine·Max JanRavindra Majeti
Sep 18, 2012·Cell Cycle·Carolina Vicente-DueñasIsidro Sánchez-García
Dec 21, 2012·Cell Cycle·Talía Velasco-HernándezDionisio Martin-Zanca
Jan 10, 2013·Nature Communications·Isabel Romero-CamareroIzidore S Lossos
Apr 10, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yussanne MaRichard S Houlston
May 2, 2013·The EMBO Journal·Carolina Vicente-DueñasIsidro Sánchez-García
Dec 25, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sara MainardiMariano Barbacid
Feb 18, 2014·Seminars in Cancer Biology·Carolina Vicente-DueñasIsidro Sánchez-García
Jun 3, 2014·Nature Communications·Michael R GreenIsidro Sánchez-García
Mar 17, 2015·Proceedings of the National Academy of Sciences of the United States of America·James Scott McClellanRavindra Majeti
May 2, 2015·Seminars in Cancer Biology·Isidro Sánchez-García
May 12, 2015·Nature Cell Biology·Ramiro Iglesias-BartolomeJ Silvio Gutkind
May 20, 2015·Nature Immunology·Srividya SwaminathanMarkus Müschen
Jul 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·David KozonoClark C Chen

❮ Previous
Next ❯

Citations

Jul 25, 2018·International Journal of Molecular Sciences·Geoffrey BrownPanagiotis Tsapogas
Sep 20, 2018·International Journal of Molecular Sciences·Geoffrey Brown, Rhodri Ceredig
Jun 4, 2019·Frontiers in Cell and Developmental Biology·Alejandro Cabezas-CruzJose de la Fuente
Mar 30, 2021·Signal Transduction and Targeted Therapy·Pian YuXiang Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Related Papers

Trends in Cancer
Carolina Vicente-DueñasIsidro Sánchez-García
Biological Chemistry
Alberto Martín-LorenzoIsidro Sánchez-García
The EMBO Journal
Carolina Vicente-DueñasIsidro Sánchez-García
© 2022 Meta ULC. All rights reserved